
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5694811/publications.pdf Version: 2024-02-01



ΕΔΝΙΖΚΔΠΝΙΔ

#	Article	lF	CITATIONS
1	Longevity of direct resin composite restorations in posterior teeth: a review. Clinical Oral Investigations, 2003, 7, 63-70.	3.0	291
2	Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut, 2003, 52, 879-885.	12.1	244
3	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 2006, 48, 623-634.	1.0	235
4	An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transplantation, 2007, 13, 1174-1180.	2.4	216
5	Adaptive designs for confirmatory clinical trials. Statistics in Medicine, 2009, 28, 1181-1217.	1.6	208
6	Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine, 2005, 24, 3697-3714.	1.6	194
7	Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials. Journal of Biopharmaceutical Statistics, 2007, 17, 965-995.	0.8	174
8	Twentyâ€five years of confirmatory adaptive designs: opportunities and pitfalls. Statistics in Medicine, 2016, 35, 325-347.	1.6	166
9	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology, 2003, 38, 1043-1050.	7.3	160
10	Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. Journal of Allergy and Clinical Immunology, 2005, 116, 347-354.	2.9	147
11	Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery, 2010, 9, 277-291.	46.4	127
12	Suicide in custody. British Journal of Psychiatry, 2004, 185, 494-498.	2.8	105
13	Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. European Journal of Clinical Pharmacology, 2010, 66, 39-48.	1.9	101
14	The reassessment of trial perspectives from interim data—a critical view. Statistics in Medicine, 2006, 25, 23-36.	1.6	95
15	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology, 2003, 38, 1043-1050.	7.3	90
16	Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242, 31-39.	1.9	89
17	Adaptive Dunnett tests for treatment selection. Statistics in Medicine, 2008, 27, 1612-1625.	1.6	89
18	Lithium in the public water supply and suicide mortality in Texas. Journal of Psychiatric Research, 2013, 47, 407-411.	3.1	88

#	Article	IF	CITATIONS
19	Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial. Journal of Clinical Epidemiology, 2020, 121, 20-28.	5.0	87
20	Cytotoxicity of four categories of dental cements. Dental Materials, 2009, 25, 360-368.	3.5	80
21	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics, 2020, 42, 1330-1360.	2.5	74
22	Role of modeling and simulation in pediatric investigation plans. Paediatric Anaesthesia, 2011, 21, 214-221.	1.1	70
23	Selection and bias—Two hostile brothers. Statistics in Medicine, 2010, 29, 1-13.	1.6	69
24	Estimation in flexible two stage designs. Statistics in Medicine, 2006, 25, 3366-3381.	1.6	65
25	Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials, 2014, 15, 383.	1.6	64
26	Cytotoxic effects of packable and nonpackable dental composites. Dental Materials, 2003, 19, 382-392.	3.5	62
27	"Thresholdâ€crossing†A Useful Way to Establish the Counterfactual in Clinical Trials?. Clinical Pharmacology and Therapeutics, 2016, 100, 699-712.	4.7	61
28	Sharing clinical trial data on patient level: Opportunities and challenges. Biometrical Journal, 2015, 57, 8-26.	1.0	60
29	Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection—Results of a Cross-Sectional Screening Study. Transplantation, 2017, 101, 631-641.	1.0	60
30	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, The, 2020, 369, m115.	6.0	57
31	Cytotoxic effects of dental bonding substances as a function of degree of conversion. Dental Materials, 2009, 25, 232-239.	3.5	55
32	Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials, 2020, 17, 472-482.	1.6	55
33	Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clinical Pharmacology and Therapeutics, 2020, 107, 773-779.	4.7	48
34	Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics, 2007, 6, 205-216.	1.3	46
35	A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid toÂassess impact on biomarkers of peritonealÂhealth. Kidney International, 2018, 94, 1227-1237.	5.2	45
36	Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal, 2015, 57, 76-89.	1.0	42

#	Article	IF	CITATIONS
37	An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis. Scientific Reports, 2021, 11, 19143.	3.3	42
38	ABO antibody and complement depletion by immunoadsorption combined with membrane filtrationa randomized, controlled, cross-over trial. Nephrology Dialysis Transplantation, 2014, 29, 706-714.	0.7	41
39	The assessment of quality of life in a trial on lightweight mesh fixation with fibrin sealant in transabdominal preperitoneal hernia repair. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2008, 12, 499-505.	2.0	40
40	Comparison of three separate antiadhesive barriers for intraperitoneal onlay mesh hernia repair in an experimental model. British Journal of Surgery, 2011, 98, 442-449.	0.3	40
41	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.8	40
42	Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. Journal of Hepatology, 2011, 54, 89-97.	3.7	39
43	IFN-γ–enhanced allergen penetration across respiratory epithelium augments allergic inflammation. Journal of Allergy and Clinical Immunology, 2005, 115, 973-981.	2.9	38
44	Characteristics of polytrauma patients between 1992 and 2002: What is changing?. Injury, 2007, 38, 1059-1064.	1.7	38
45	Reading performance depending on the type of cataract and its predictability on the visual outcome. Journal of Cataract and Refractive Surgery, 2004, 30, 1259-1267.	1.5	37
46	Cytotoxicity of resin composites as a function of interface area. Dental Materials, 2007, 23, 1438-1446.	3.5	32
47	Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials. PLoS ONE, 2016, 11, e0146465.	2.5	32
48	A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. Liver International, 2010, 30, 574-582.	3.9	31
49	Conditional Rejection Probabilities of Student'st-test and Design Adaptations. Biometrical Journal, 2004, 46, 389-403.	1.0	30
50	Improved Repeated Confidence Bounds in Trials with a Maximal Goal. Biometrical Journal, 2003, 45, 311-324.	1.0	29
51	The impact of colonyâ€stimulating factorâ€1 on fracture healing: An experimental study. Journal of Orthopaedic Research, 2009, 27, 36-41.	2.3	29
52	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Medicine, 2018, 16, 210.	5.5	28
53	Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 2019, 28, 2096-2111.	1.5	28
54	Cytotoxicity of a calcium aluminate cement in comparison with other dental cements and resin-based materials. Acta Odontologica Scandinavica, 2006, 64, 1-8.	1.6	27

#	Article	IF	CITATIONS
55	Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency. Trials, 2018, 19, 642.	1.6	26
56	Subgroup identification in clinical trials via the predicted individual treatment effect. PLoS ONE, 2018, 13, e0205971.	2.5	26
57	Cytotoxicity and shear bond strength of four orthodontic adhesive systems. European Journal of Orthodontics, 2008, 30, 495-502.	2.4	25
58	Evidence, eminence and extrapolation. Statistics in Medicine, 2016, 35, 2117-2132.	1.6	24
59	Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discovery Today, 2018, 23, 424-433.	6.4	24
60	Optimizing Trial Designs for Targeted Therapies. PLoS ONE, 2016, 11, e0163726.	2.5	24
61	Geriatric polytrauma. Wiener Klinische Wochenschrift, 2005, 117, 145-149.	1.9	23
62	Combination of anorganic bovine-derived hydroxyapatite with binding peptide does not enhance bone healing in a critical-size defect in a rabbit model. Journal of Orthopaedic Research, 2008, 26, 759-763.	2.3	23
63	Lessons learned from IDeAl — 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 77.	2.7	22
64	Modified solid-phase alloantibody detection for improved crossmatch prediction. Human Immunology, 2013, 74, 32-40.	2.4	21
65	Clinical trials for authorized biosimilars in the European Union: a systematic review. British Journal of Clinical Pharmacology, 2016, 82, 1444-1457.	2.4	21
66	Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biometrical Journal, 2014, 56, 614-630.	1.0	20
67	An update on the clinical evidence that supports biosimilar approvals in Europe. British Journal of Clinical Pharmacology, 2018, 84, 1415-1431.	2.4	19
68	Fixation of femoral fractures in multiple-injury patients with combined chest and head injuries. ANZ Journal of Surgery, 2003, 73, 1018-1021.	0.7	18
69	Functional Recovery at a Minimum of 2 Years After Multiple Injury—Development of an Outcome Score. Journal of Trauma, 2008, 65, 799-808.	2.3	18
70	Design and estimation in clinical trials with subpopulation selection. Statistics in Medicine, 2018, 37, 4335-4352.	1.6	18
71	Systematic review of available software for multi-arm multi-stage and platform clinical trial design. Trials, 2021, 22, 183.	1.6	18
72	Vascular endothelial growth factor (VEGF) and discrimination between abnormal intrauterine and ectopic pregnancy. Human Reproduction, 2002, 17, 3231-3234.	0.9	17

#	Article	IF	CITATIONS
73	An Adaptive Hierarchical Test Procedure for Selecting Safe and Efficient Treatments. Biometrical Journal, 2006, 48, 663-678.	1.0	17
74	Analysis of Austrian COVID-19 deaths by age and sex. Wiener Klinische Wochenschrift, 2020, 132, 685-689.	1.9	16
75	Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine, 2009, 28, 1321-1338.	1.6	15
76	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of Endâ€stage Liver Disease score. European Journal of Clinical Investigation, 2009, 39, 65-71.	3.4	15
77	Adaptive graphâ€based multiple testing procedures. Pharmaceutical Statistics, 2014, 13, 345-356.	1.3	15
78	Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. Transplant International, 2015, 28, 820-827.	1.6	14
79	Commentary on Parker and Weir. Clinical Trials, 2020, 17, 567-569.	1.6	14
80	Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. Pharmaceutical Statistics, 2021, 20, 129-145.	1.3	14
81	Do monthly or seasonal variations exist in suicides in a high-risk setting?. Psychiatry Research, 2004, 121, 263-269.	3.3	13
82	The risks of methodology aversion in drug regulation. Nature Reviews Drug Discovery, 2014, 13, 317-318.	46.4	13
83	Interim analysis incorporating short―and longâ€ŧerm binary endpoints. Biometrical Journal, 2019, 61, 665-687.	1.0	12
84	A critical review of graphics for subgroup analyses in clinical trials. Pharmaceutical Statistics, 2020, 19, 541-560.	1.3	12
85	Optimizing subgroup selection in twoâ€stage adaptive enrichment and umbrella designs. Statistics in Medicine, 2021, 40, 2939-2956.	1.6	11
86	Decision rules for identifying combination therapies in openâ€entry, randomized controlled platform trials. Pharmaceutical Statistics, 2022, 21, 671-690.	1.3	11
87	One-year evaluation of two hybrid composites placed in a randomized-controlled clinical trial. Dental Materials, 2014, 30, 824-838.	3.5	10
88	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, 2020, 21, 528.	1.6	10
89	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	2.8	10
90	Effects of a Femoral Shaft Fracture on Multiply Injured Patients with a Head Injury. World Journal of Surgery, 2003, 27, 365-369.	1.6	9

#	Article	IF	CITATIONS
91	Clearance of Selected Plasma Cytokines with Continuous Veno-Venous Hemodialysis Using Ultraflux EMiC2 versus Ultraflux AV1000S. Blood Purification, 2017, 44, 260-266.	1.8	8
92	Estimation after blinded sample size reassessment. Statistical Methods in Medical Research, 2018, 27, 1830-1846.	1.5	8
93	Sample Size for Multiple Hypothesis Testing in Biosimilar Development. Statistics in Biopharmaceutical Research, 2018, 10, 39-49.	0.8	8
94	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. Statistics in Medicine, 2018, 37, 3387-3402.	1.6	8
95	Analysis of Inflammatory Mediator Profiles in Sepsis Patients Reveals That Extracellular Histones Are Strongly Elevated in Nonsurvivors. Mediators of Inflammation, 2021, 2021, 1-13.	3.0	8
96	Transjugular intrahepatic portosystemic shunt in Vienna – A decade later. Wiener Klinische Wochenschrift, 2004, 116, 608-613.	1.9	7
97	The Distillation of "VISCI― Towards a Better Identification of Suicidal Inmates. Suicide and Life-Threatening Behavior, 2009, 39, 376-385.	1.9	7
98	Nested combination tests with a timeâ€ŧoâ€event endpoint using a shortâ€ŧerm endpoint for design adaptations. Pharmaceutical Statistics, 2019, 18, 329-350.	1.3	7
99	COVID-19 is not "just another flu†a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. Infection, 2021, 49, 907-916.	4.7	7
100	Degeneration and Instability and the Relation to Patients' Function Late After Lumbar Disc Surgery. American Journal of Physical Medicine and Rehabilitation, 2016, 95, 871-879.	1.4	6
101	A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics, 2018, 17, 593-606.	1.3	6
102	Robust group sequential designs for trials with survival endpoints and delayed response. Biometrical Journal, 2022, 64, 343-360.	1.0	5
103	Effect of Information on Reported Adverse Events in a Placebo-Controlled Trial. Drug Safety, 2005, 28, 81-87.	3.2	4
104	Suicide prevention in correctional institutions: The significance of solitary cell accommodation. International Journal of Prisoner Health, 2007, 3, 225-232.	0.9	4
105	MCP2007 – 5th International Conference on Multiple Comparison Procedures. Biometrical Journal, 2008, 50, 633-635.	1.0	3
106	Adaptive paediatric investigation plans, a small step to improve regulatory decision making in drug development for children?. Pharmaceutical Statistics, 2016, 15, 384-386.	1.3	3
107	Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clinical Microbiology and Infection, 2022, 28, 596-601.	6.0	3
108	Testing and Interpreting the "Right―Hypothesis—Comment on "Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials― Statistics in Biopharmaceutical Research, 2023, 15, 310-311.	0.8	3

#	Article	IF	CITATIONS
109	The scientific work of Peter Bauer. Biometrical Journal, 2007, 49, 651-653.	1.0	2
110	Health-related quality of life of long-term survivors of intensive care: changes after intensive care treatment. Wiener Klinische Wochenschrift, 2012, 124, 624-632.	1.9	2
111	Composite Outcome Improves Feasibility of Clinical Trials in Peritoneal Dialysis. Peritoneal Dialysis International, 2019, 39, 479-485.	2.3	2
112	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. Statistical Methods in Medical Research, 2020, 29, 1483-1498.	1.5	2
113	Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on "The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations― Statistics in Biopharmaceutical Research, 2021, 13, 43-45.	0.8	2
114	Many-to-one comparisons after safety selection in multi-arm clinical trials. PLoS ONE, 2017, 12, e0180131.	2.5	2
115	Monitoring Daily Ultrafiltration in Automated Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 107-110.	4.5	2
116	Authors' response to comments. Statistics in Medicine, 2016, 35, 364-367.	1.6	1
117	Multiple Test Strategies for Comparing Several Doses with a Control in Confirmatory Trials. , 2017, , 279-290.		1
118	Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat17(5):593â€606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873. Pharmaceutical Statistics, 2019, 18, 284-286.	1.3	1
119	A multiple comparison procedure for doseâ€finding trials with subpopulations. Biometrical Journal, 2020, 62, 53-68.	1.0	1
120	Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development. Statistics in Biopharmaceutical Research, 2021, 13, 106-112.	0.8	1
121	Selecting predictive biomarkers from genomic data. PLoS ONE, 2022, 17, e0269369.	2.5	1
122	SuO013ALANYL-GLUTAMINE IN PERITONEAL DIALYSIS FLUIDS IMPROVES PERITONEAL HEALTH AND SYSTEMIC INFLAMMATION: A DOUBLE-BLINDED RANDOMIZED CROSSOVER TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i621-i621.	0.7	0
123	Assessing mechanical catheter dysfunction in automated tidal peritoneal dialysis using cycler software: a case control, proof-of-concept study. Scientific Reports, 2022, 12, 5657.	3.3	0
124	MO679: Peritonitis May Disrupt Cyclic Periodicity of Ultrafiltration in Peritoneal Dialysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
125	MO669: Predictive Parameters of Automated PD Cycler Software for Diagnosis of Catheter Dysfunction. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0